Remove Coronary Artery Disease Remove Innovation Remove Medicare
article thumbnail

Cleerly Raises $106 Million in Series C Extension Funding

DAIC

Cleerly is dedicated to creating a new standard of care for heart disease by using FDA-cleared solutions powered by artificial intelligence. With this investment, we look forward to helping Cleerly expand its reach and impact, bringing this potentially life-saving innovation to more patients and health systems nationally.

article thumbnail

FDA Breakthrough Device Designation for Biotronik Freesolve Below-the-Knee Resorbable Magnesium Scaffold (RMS)

DAIC

“Biotronik 's focus on vascular interventional excellence is evident in our strategic investments and persistent dedication to innovation”, said Dr. Jörg Pochert, President of Vascular Intervention at Biotronik. For more information: www.biotronik.com References: 1 Kwong M.,

article thumbnail

HeartFlow Announces Revolutionary Five-Year Data Demonstrating a 63 Percent Mortality Reduction with FFRCT-Guided Care in PAD Patients

DAIC

1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronary artery disease (CAD), historically linked with a mortality rate exceeding 50 percent within five years. 301–302, [link]. 3 Secemsky, Eric A.,

article thumbnail

Elixir Medical Granted FDA Breakthrough Device Designation for DynamX Bioadaptor

DAIC

The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease. The DynamX bioadaptor has a novel design and mechanism of action designed to return the diseased vessel to a more normal condition, through three distinct phases.

article thumbnail

HeartFlow Achieves Landmark Milestone of 250,000 Patients Assessed for Coronary Artery Disease (CAD) with FFRCT Analysis

DAIC

With more than 500 peer-reviewed publications, the HeartFlow FFR CT Analysis remains unparalleled in precision coronary care, as supported by the ACC/AHA Chest Pain Guidelines, to improve treatment plans and outcomes. 3 HeartFlow’s FFR CT Analysis is covered by Medicare and for >99% of commercially insured lives.

article thumbnail

The Evolving Computed Tomography Market

DAIC

I think especially with the recent changes in guidelines and the recommendation to use CT for screening of coronary artery disease, we expect to see this trend really impact the way CT is used in the future.” “The CT procedural mix is evolving, and cardiac CT is starting to account for a large proportion of that.

article thumbnail

Latest developments in the Cardiac Healthcare system through AI

Wellnest

The development has urged us to integrate the latest Artificial Intelligence with the healthcare system, including Cardiac Medicare. With the continued evolution of AI, it is now being introduced in cardiac healthcare, promising opportunities for innovation and advancements in cardiovascular medicine. What is Artificial Intelligence?